Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares BioPharma DiveIndustry executives can share their views on the national priority program at a June meeting.RegulatoryRead full story pharminent March 24, 2026 BioPharma Dive Industry executives can share their views on the national priority program at a June meeting. Regulatory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit ManagersNext: Immutrin raises $87M to advance drug for progressive heart disease Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
